« Return to News | R&D Trends

Covance enters R&D collaboration

Thursday, January 19, 2012 08:30 AM

Covance, Inserm Transfert, a subsidiary of Inserm, and seed investment company Inserm Transfert Initiative have signed a four-year R&D collaboration.

Covance’s France- and U.K.-based facilities will conduct discovery and early development studies for Inserm, its subsidiary, and startups within Inserm Transfert Initiative’s portfolio. The startups will also gain access to Covance’s scientific, operational and program management expertise.

Covance experts will advise representatives from Inserm Transfert and Inserm Transfert Initiative to help select projects that will most benefit from Covance’s drug discovery and drug development capabilities.

“The robust resources Covance brings will help our startup companies grow more quickly and efficiently,” said Matthieu Coutet, investment director of Inserm Transfert Initiative. “Covance will provide important strategic guidance to help them establish and implement early clinical development plans with the right technical know-how and management support.”

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.